bl-m17d1
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 24, 2024 (NCT06500052)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Lung Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Urologic Neoplasms · Phase 1
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06714617 | Phase 1 | Mar 1, 2025 | SystImmune Inc. |
| NCT06503783 | Phase 1 | Aug 24, 2024 | Baili Pharmaceutical Group |
| NCT06500052 | Phase 1 | Jul 24, 2024 | Baili Pharmaceutical Group, Sun Yat-Sen University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 2 | 2 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| SystImmune Inc. | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1